Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.

Sanchit SharmaRamesh KumarGyanranjan RoutShivanand R Gamanagatti. Shalimar

Published in: Journal of gastroenterology and hepatology (2019)

Dabigatran, as compared with vitamin K antagonists, is associated with similar stent patency rates and complications among patients with Budd-Chiari syndrome post-endovascular intervention.

Keyphrases

atrial fibrillation
randomized controlled trial
inferior vena cava
case report
venous thromboembolism
minimally invasive
risk factors
aortic dissection
ultrasound guided
pulmonary embolism